Aldeyra Therapeutics Stock Discussion

$Aldeyra Therapeutics(ALDX.US)$ Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease expected to submit to FDA in  2H

$Aldeyra Therapeutics(ALDX.US)$
NEWS
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Positive
Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease.
Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...

$Aldeyra Therapeutics(ALDX.US)$ Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

$Aldeyra Therapeutics(ALDX.US)$ATTENTION LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to Januar...

$Aldeyra Therapeutics(ALDX.US)$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 504.27K shares of Common Stock on Apr 1, 2, 3, 2024 at an average price of $3.84 for a total value of $1.93 million.

$Aldeyra Therapeutics(ALDX.US)$ • AbbVie (NYSE:ABBV) has extended the period during which it can exercise an option for a co-development, co-commercialization and license agreement with Aldeyra Therapeutics (NASDAQ:ALDX) for dry eye candidate reproxalap.
• As a result, AbbVie (ABBV) is paying a non-refundable $5M option extension fee.
• The original option agreement was signed in late October.
• AbbVie (ABBV) now can exercise its option by the earlier of (a) the 10th business day after ...

$Aldeyra Therapeutics(ALDX.US)$ The daily finished with a big ole hammer! So lets see if it gets a nice PI tomorrow? Hell why not get a head start in AH? hehehe